Richard Friedman to Arthroplasty, Replacement, Knee
This is a "connection" page, showing publications Richard Friedman has written about Arthroplasty, Replacement, Knee.
Connection Strength
9.079
-
Effects of the Obesity Epidemic on Total Hip and Knee Arthroplasty Demographics. J Arthroplasty. 2021 09; 36(9):3097-3100.
Score: 0.633
-
Current Controversies in Total Knee Arthroplasty-Part 2. J Knee Surg. 2019 08; 32(8):703.
Score: 0.562
-
Current Controversies in Total Knee Arthroplasty-Part 1. J Knee Surg. 2019 07; 32(7):589.
Score: 0.558
-
All-Polyethylene versus Metal-Backed Tibial Components in Total Knee Arthroplasty. J Knee Surg. 2019 Aug; 32(8):714-718.
Score: 0.549
-
Resurfaced versus Non-Resurfaced Patella in Total Knee Arthroplasty. J Knee Surg. 2019 Jul; 32(7):611-615.
Score: 0.545
-
Minimizing Blood Loss and Transfusions in Total Knee Arthroplasty. J Knee Surg. 2018 Aug; 31(7):594-599.
Score: 0.515
-
Navigation in Total Knee Arthroplasty: A Procedure Whose Time Has Not Come: Commentary on an article by Young-Hoo Kim, MD, et al.: "The Clinical Outcome of Computer-Navigated Compared with Conventional Knee Arthroplasty in the Same Patients. A Prospective, Randomized, Double-Blind, Long-Term Study". J Bone Joint Surg Am. 2017 06 21; 99(12):e64.
Score: 0.485
-
Making Tranexamic Acid the Standard of Care in Hip and Knee Arthroplasty: Commentary on an article by Brian Hallstrom, MD, et al.: "The Michigan Experience with Safety and Effectiveness of Tranexamic Acid Use in Hip and Knee Arthroplasty". J Bone Joint Surg Am. 2016 10 05; 98(19):e86.
Score: 0.462
-
Clinical experience with novel oral anticoagulants for thromboprophylaxis after elective hip and knee arthroplasty. Arterioscler Thromb Vasc Biol. 2015 Apr; 35(4):771-8.
Score: 0.414
-
Allogeneic blood transfusions and postoperative infections after total hip or knee arthroplasty. J Bone Joint Surg Am. 2014 Feb 19; 96(4):272-8.
Score: 0.385
-
Complication rates after hip or knee arthroplasty in morbidly obese patients. Clin Orthop Relat Res. 2013 Oct; 471(10):3358-66.
Score: 0.365
-
Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid in patients undergoing total hip and total knee arthroplasty: no increased risk of bleeding. Thromb Haemost. 2012 Jul; 108(1):183-90.
Score: 0.340
-
Economic impact of venous thromboembolism after hip and knee arthroplasty: potential impact of rivaroxaban. Expert Rev Pharmacoecon Outcomes Res. 2011 Jun; 11(3):299-306.
Score: 0.319
-
Limit the bleeding, limit the pain in total hip and knee arthroplasty. Orthopedics. 2010 Sep; 33(9 Suppl):11-3.
Score: 0.303
-
Practice patterns in the use of venous thromboembolism prophylaxis after total joint arthroplasty--insights from the Multinational Global Orthopaedic Registry (GLORY). Am J Orthop (Belle Mead NJ). 2010 Sep; 39(9 Suppl):14-21.
Score: 0.303
-
Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials. Thromb Res. 2010 Sep; 126(3):175-82.
Score: 0.297
-
New oral anticoagulants for thromboprophylaxis after total hip or knee arthroplasty. Orthopedics. 2009 Dec; 32(12 Suppl):79-84.
Score: 0.287
-
Dabigatran etexilate: pivotal trials for venous thromboembolism prophylaxis after hip or knee arthroplasty. Clin Appl Thromb Hemost. 2009 Sep-Oct; 15 Suppl 1:25S-31S.
Score: 0.281
-
Physician compliance with guidelines for deep-vein thrombosis prevention in total hip and knee arthroplasty. Curr Med Res Opin. 2008 Jan; 24(1):87-97.
Score: 0.252
-
Optimal duration of prophylaxis for venous thromboembolism following total hip arthroplasty and total knee arthroplasty. J Am Acad Orthop Surg. 2007 Mar; 15(3):148-55.
Score: 0.237
-
Extended thromboprophylaxis after hip or knee replacement. Orthopedics. 2003 Feb; 26(2 Suppl):s225-30.
Score: 0.179
-
The role of low molecular weight heparin in total knee arthroplasty. Am J Knee Surg. 1999; 12(1):55-60.
Score: 0.135
-
Benefit-risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty. Vasc Health Risk Manag. 2014; 10:157-67.
Score: 0.097
-
Dabigatran is effective with a favourable safety profile in normal and overweight patients undergoing major orthopaedic surgery: a pooled analysis. Thromb Res. 2012 Nov; 130(5):818-20.
Score: 0.086
-
Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty. Thromb Res. 2012 Aug; 130(2):147-51.
Score: 0.083
-
Prevention of venous thromboembolism after hip or knee arthroplasty: findings from a 2008 survey of US orthopedic surgeons. J Arthroplasty. 2012 May; 27(5):659-66.e5.
Score: 0.082
-
New oral anticoagulants for venous thromboembolism prophylaxis in orthopaedic surgery. Instr Course Lect. 2011; 60:291-300.
Score: 0.077
-
Potent anticoagulants are associated with a higher all-cause mortality rate after hip and knee arthroplasty. Clin Orthop Relat Res. 2008 Aug; 466(8):2009-11; author reply 2012-4.
Score: 0.065
-
Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009 Jan; 24(1):1-9.
Score: 0.064
-
Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events: findings from the Global Orthopaedic Registry. J Bone Joint Surg Br. 2007 Jun; 89(6):799-807.
Score: 0.060
-
Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. Enoxaparin Clinical Trial Group. J Bone Joint Surg Am. 2001 Mar; 83(3):336-45.
Score: 0.039
-
Lessons learned from the global orthopaedic registry: study design, current practice patterns, and future directions. Am J Orthop (Belle Mead NJ). 2010 Sep; 39(9 Suppl):29-31.
Score: 0.019